PLEKHB2

Across TCGA pan-cancer cohorts, PLEKHB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHB2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PLEKHB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, STAD, and BRCA are the cancer types where PLEKHB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.167	0.542	.005	36	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.001	30	view →
BRCA	DFS	Median	III,IV	0.093	0.880	<.001	24	view →
KIRP	OS	Median	All	0.177	0.694	.001	6	view →
UCEC	DFS	Median	All	0.953	0.622	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHB2–OV (DFS)

Open the OV breakdown →